Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.Cantor analyst Josh Schimmer initiated coverage at an Overweight rating with a price target of $50.The analyst says that SEPN’s advanced platform accelerates the discovery of novel GPCR-targeting therapeutics, addressing a significant unmet need.Leveraging CryoEM technology, SEPN reconstitutes GPCRs in lipid bilayers, enabling structural analysis of targets previously deemed “undruggable.” This unlocks potenti ...